Healio

Subcutaneous Remsima non-inferior to IV formulation

Please provide your email address to receive an email when new articles are posted on . The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity ...
JD Supra

Celltrion to Launch REMSIMA SC (infliximab) in Europe in March, 2020

Multiple sources are reporting that Celltrion is planning to roll out REMSIMA SC, its subcutaneous infliximab biosimilar of Johnson & Johnson’s autoimmune disease treatment REMICADE, in Europe in the ...
Business Wire

New data presented at UEG Week Virtual 2020 show positive association between Remsima® SC pre-dose level with efficacy outcomes

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced two new data sets relating to the use of the subcutaneous formulation of infliximab, Remsima ® SC (CT-P13 SC), in ...
Business Wire

Celltrion Healthcare receives EU marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC™, for the treatment of people with rheumatoid ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...
FiercePharma

Celltrion makes case for Remicade biobetter with subcut switch data

Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
Healio

European Commission expands approved indications for subcutaneous infliximab biosimilar

Please provide your email address to receive an email when new articles are posted on . The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to ...
FiercePharma

EU backs fully subcutaneous regimen of Remicade biobetter

The European Medicines Agency (EMA) has backed the use of Celltrion Healthcare’s subcutaneous infliximab without initial intravenous loading doses. Securing the regulatory recommendation boosts ...
Business Insider

Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix ...

EXTON, Pa., Nov. 9, 2020 /PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists ...
조선일보

Celltrion's Zympentra shows consistent efficacy across Crohn disease inflammation sites

Celltrion said on the 26th that the post hoc analysis results of the global phase 3 clinical trial of Zympentra, the subcutaneous (SC) formulation of the autoimmune disease treatment Remsima ...
Business Insider

Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima™ SC, for the treatment of people with ...

TORONTO, Feb. 1, 2021 /CNW Telbec/ - Celltrion Healthcare Canada Limited announced today that Health Canada has granted a notice of compliance (NOC) for Remsima™ SC (CT-P13 SC) in Canada for the ...